Active Biotech's Prostate Cancer Project TASQ Featured in Journal of Clinical Oncology
(Thomson Reuters ONE) -
Lund, Sweden, September 20, 2011 - the Journal of Clinical Oncology
(http://jco.ascopubs.org/content/early/recent) has published an article*
presenting results from a controlled clinical Phase II study in 201 evaluable
patients of Active Biotech's (NASDAQ OMX Nordic: ACTI) prostate cancer project
TASQ.
It was concluded in the study that TASQ significantly slowed disease progression
and improved Progression Free Survival (PFS) in patients with metastatic
castrate-resistant prostate cancer (CRPC), alongside an acceptable side effect
profile. Six month progression free proportion of patients for TASQ and placebo
treatment groups were 69% and 37%, respectively (p<0.0001), with a median PFS of
7.6 vs. 3.3 months (p=0.0042).
Enrollment of patients to a pivotal Phase III trial was initiated in March
2011. The Phase III study is a global, randomized, double-blind, placebo-
controlled study in patients with metastatic CRPC. The aim of the study is to
confirm TASQ's effect on the disease, with radiological PFS as the primary
endpoint and overall survival as secondary endpoint. The planned study will
include about 1,200 patients in more than 250 clinics.
Active Biotech AB (publ)
Tomas Leanderson
President & CEO
For further information, please contact
Tomas Leanderson, President & CEO
Tel: +46 46 19 20 95
tomas.leanderson(at)activebiotech.com
*Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in
Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Pili, R.,, Häggman, M., Stadler. W., Gingrich, J., Assikis, V., Björk, A.,
Nordle, Ö., Forsberg, G., Carducci, M., Armstrong, A.
Notes to editors
About TASQ
The development of TASQ is principally focused on the treatment ofprostate
cancer. TASQ is an antiangiogenic compound, meaning that it cuts off the supply
of nutrients to the tumor. Studies have concluded that TASQ exhibits anti-tumor
activity via inhibition of tumor angiogenesis. The up-regulation of the
antiangiogenic protein thrombospondin-1 (TSP1) is a part of this mechanism. It
was announced in December 2009 that the primary endpoint of the Phase II
clinical study, to show a higher fraction of patients with no disease
progression during the six-month period of treatment using TASQ, had been met.
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, TASQ for
prostate cancer and ANYARA for use in cancer targeted therapy, primarily of
renal cell cancer. In addition, laquinimod is in Phase II development for
Crohn's and Lupus. Further projects in clinical development comprise the two
orally administered compounds, 57- 57 for Systemic Sclerosis as well as
RhuDex(TM) for RA. Please visit www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is required under the Financial Instruments Trading Act to make
the information in this press release public. The information was submitted for
publication at 08:30 a.m. CET on September 20, 2011.
Active Biotech?s Prostate Cancer Project TASQ Featured in JCO:
http://hugin.info/1002/R/1548081/475708.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1548081]
Unternehmensinformation / Kurzprofil:
Datum: 20.09.2011 - 08:30 Uhr
Sprache: Deutsch
News-ID 67429
Anzahl Zeichen: 4582
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 269 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Active Biotech's Prostate Cancer Project TASQ Featured in Journal of Clinical Oncology"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
